ArticleRegenerative therapy2026
Long-term outcomes of middle ear regenerative therapy using cell sheet transplantation combined with tympanoplasty.
Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Regenerative medicine using autologous mucosa-derived epithelial cell sheets has attracted increasing attention as a novel therapeutic strategy for reconstructing epithelial tissues. We have developed a new regenerative treatment for middle ear diseases, including cholesteatoma, using autologous nasal mucosal epithelial cell sheets, and conducted clinical studies demonstrating its potential to suppress postoperative recurrence. In this study, we evaluated the long-term clinical outcomes of patients treated with this approach. Methods: In our clinical research project, six patients with acquired cholesteatoma underwent canal wall up tympanoplasty with mastoidectomy combined with autologous nasal mucosal epithelial cell sheet transplantation between 2014 and 2019. Four patients who were followed up for more than five years after transplantation were included in this long-term analysis. Postoperative outcomes were assessed based on mastoid cavity aeration on computed tomography (CT), hearing outcomes, recurrence of cholesteatoma, and transplantation-related adverse events. Results: Mean follow-up was 9.25 years (range: 6.5-11.5 years). All patients maintained successful mastoid aeration throughout the study, with mean CT areas of 216.08 ± 75.87 mm Conclusion: Canal wall up tympanoplasty with mastoidectomy combined with autologous nasal mucosal epithelial cell sheet transplantation is a safe and effective long-term regenerative treatment for middle ear diseases. This therapy contributes to sustained aeration and prevention of recurrence through regeneration of the middle ear mucosa and may represent the first regenerative medicine product for clinical application in otology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.